Published in Curr Med Res Opin on December 31, 2014
A Review on Iron Chelators in Treatment of Iron Overload Syndromes. Int J Hematol Oncol Stem Cell Res (2016) 0.76
How we manage iron overload in sickle cell patients. Br J Haematol (2017) 0.75
High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med (2007) 5.18
Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease. Cancer (2013) 2.10
Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol (2006) 1.89
Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med (2010) 1.75
Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia (2007) 1.70
Sickle cell pain: a critical reappraisal. Blood (2012) 1.69
Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension (2012) 1.65
Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalization. Neurology (2012) 1.62
The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD (2010) 1.59
Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics. Med Oncol (2011) 1.55
Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia. Cancer (2009) 1.54
Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin. Transfusion (2009) 1.53
Removal of opioid/acetaminophen combination prescription pain medications: assessing the evidence for hepatotoxicity and consequences of removal of these medications. Pain Med (2010) 1.51
Incremental direct and indirect costs of untreated vasomotor symptoms. Menopause (2015) 1.45
The economic impact of pre-dialysis epoetin alpha on health care and work loss costs in chronic kidney disease: an employer's perspective. Dis Manag (2008) 1.38
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica (2012) 1.35
Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study. Epilepsia (2008) 1.32
Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective. J Manag Care Pharm (2009) 1.25
Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer (2006) 1.20
Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. BJU Int (2009) 1.17
Hemodynamic predictors of mortality in adults with sickle cell disease. Am J Respir Crit Care Med (2013) 1.16
Cytokine-mediated increases in fetal hemoglobin are associated with globin gene histone modification and transcription factor reprogramming. Blood (2009) 1.15
Red blood cell transfusions and the risk of acute respiratory distress syndrome among the critically ill: a cohort study. Crit Care (2007) 1.14
The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol (2008) 1.13
Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia. J Natl Compr Canc Netw (2005) 1.06
Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting. Curr Med Res Opin (2008) 1.04
Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa. Curr Med Res Opin (2006) 1.03
Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause (2011) 1.03
Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices. Transfusion (2009) 0.99
Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther (2012) 0.98
Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol (2008) 0.95
Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma. Ann Allergy Asthma Immunol (2012) 0.95
Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism. Patient (2013) 0.94
Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs. Pediatr Blood Cancer (2013) 0.94
Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need. Transfusion (2012) 0.94
Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy. BMC Cancer (2011) 0.92
Impact of chronic hand dermatitis on quality of life, work productivity, activity impairment, and medical costs. J Am Acad Dermatol (2006) 0.91
Entropy and bispectral index for assessment of sedation, analgesia and the effects of unpleasant stimuli in critically ill patients: an observational study. Crit Care (2008) 0.91
Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries. Curr Med Res Opin (2009) 0.91
Medical costs of untreated anemia in elderly patients with predialysis chronic kidney disease. J Am Soc Nephrol (2006) 0.90
Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy. Epilepsy Behav (2011) 0.90
Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes. Appl Health Econ Health Policy (2014) 0.90
Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review. Support Care Cancer (2008) 0.89
Cost burden and treatment patterns associated with management of heavy menstrual bleeding. J Womens Health (Larchmt) (2012) 0.89
Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. BMC Psychiatry (2013) 0.88
A transition pilot program for adolescents with sickle cell disease. J Pediatr Health Care (2012) 0.88
Acute chest syndrome: sickle cell disease. Eur J Haematol (2011) 0.88
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review. Int J Oncol (2013) 0.87
A randomized phase II trial of Arginine Butyrate with standard local therapy in refractory sickle cell leg ulcers. Br J Haematol (2010) 0.87
Lifetime costs to Medicare of providing care to patients with chronic lymphocytic leukemia. Leuk Lymphoma (2012) 0.86
Clinical outcomes, quality of life, and costs associated with implantation of vagus nerve stimulation therapy in pediatric patients with drug-resistant epilepsy. Eur J Paediatr Neurol (2012) 0.86
All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries. J Manag Care Pharm (2012) 0.86
Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting. Curr Med Res Opin (2015) 0.85
Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA. J Ophthalmic Inflamm Infect (2013) 0.85
Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden. J Med Econ (2015) 0.85
Systematic literature review of the costs of pregnancy in the US. Pharmacoeconomics (2013) 0.84
Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia. Curr Med Res Opin (2014) 0.84
Identification of hemochromatosis gene polymorphisms in chronically transfused patients with sickle cell disease. Am J Hematol (2003) 0.84
The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease. Value Health (2008) 0.84
Utility values for specific chronic myeloid leukemia chronic phase health states from the general public in the United Kingdom. Leuk Lymphoma (2014) 0.83
Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database. J Med Econ (2009) 0.83
Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers. J Neurol Sci (2013) 0.83
Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics. J Med Econ (2013) 0.82
Costs, quality of life and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: a review of the literature. Expert Opin Pharmacother (2008) 0.82
Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population. J Med Econ (2011) 0.81
The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer (2007) 0.81
Resource utilization associated with irritable bowel syndrome in the United States 1987-1997. Dig Dis Sci (2002) 0.81
Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review. J Cancer Res Ther (2010) 0.81
A survey-based assessment of the prevalence and severity of chronic hand dermatitis in a managed care organization. Cutis (2006) 0.80
Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations. Curr Med Res Opin (2006) 0.80
Dose and cost comparison of erythropoietic agents in the inpatient hospital setting. Am J Health Syst Pharm (2007) 0.80
Burden of schizophrenia on selected comorbidity costs. Expert Rev Pharmacoecon Outcomes Res (2014) 0.80
Economic burden associated with the use of generic antiepileptic drugs in the United States. Epilepsy Behav (2010) 0.79
Pharmacoeconomic considerations in treating iron overload in patients with β-thalassaemia, sickle cell disease and myelodysplastic syndromes in the US: a literature review. Pharmacoeconomics (2011) 0.78
Comparison of the long-term risk of recurrence and other clinical outcomes in GIST patients receiving imatinib as adjuvant therapy--a retrospective chart extract-based approach. J Gastrointest Cancer (2013) 0.78
The direct and indirect cost burden of atopic dermatitis: an employer-payer perspective. Manag Care Interface (2007) 0.78
Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States. J Med Econ (2012) 0.78
Prevalence of 25-hydroxyvitamin D deficiency in an urban general internal medicine academic practice. Tenn Med (2010) 0.78
Treatment patterns, prescribing decision drivers, and predictors of complete response following disease recurrence in gastrointestinal stromal tumor patients-a chart extract-based approach. J Gastrointest Cancer (2014) 0.78
Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy. Menopause (2016) 0.78
Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil: a retrospective, parallel-cohort, hypothesis-generating study. Drugs Aging (2010) 0.77
Association of self-monitoring of blood glucose use on glycated hemoglobin and weight in newly diagnosed, insulin-naïve adult patients with type 2 diabetes. J Diabetes Sci Technol (2013) 0.77
Sepsis caused by Mycobacterium terrae complex in a patient with sickle cell disease. BMJ Case Rep (2013) 0.77
Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis. J Med Econ (2015) 0.77
Psychometric validation of the Patient Symptom Assessment in Lung Cancer instrument for small cell lung cancer. Curr Med Res Opin (2007) 0.77
Symptom assessment in relapsed small cell lung cancer: cross-validation of the patient symptom assessment in lung cancer instrument. J Thorac Oncol (2008) 0.77
Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs. J Med Econ (2012) 0.76
Risk of hepatotoxicity-related hospitalizations among patients treated with opioid/acetaminophen combination prescription pain medications. Pain Med (2010) 0.76